

**LISTING OF CLAIMS:**

The following is a marked-up version the Claims pursuant to 37 C.F.R. §1.121 (c)(1)(ii) with instructions and markings showing changes made herein to the previous version of the Claims on record. Underlining denotes added text while strikeout denotes deleted text.

1. (Cancelled)
2. (Currently Amended) A reduced allergenic variant of a polypeptide of interest, wherein said polypeptide of interest is selected from the group consisting of cellulases, lipases, endoglucosidase H, carbohydrases, reductases, oxidases, isomerases, transferases, kinases, and phosphatases, ~~wherein said kinase is not streptokinase~~, and said polypeptide of interest comprises a T-cell epitope,  
wherein said variant differs from said polypeptide of interest by having an altered T-cell epitope such that one or more amino acid residues of the T-cell epitope are altered and  
wherein an allergenic immunogenic response produced by said variant in an individual is less than said allergenic immunogenic response produced by said polypeptide of interest.
3. (Cancelled)
4. (Cancelled)
5. (Previously Amended) The variant of claim 2, wherein said polypeptide of interest is not recognized by said individual as endogenous to said individual.
6. (Cancelled)
7. (Previously Amended) The variant of claim 2, wherein said T-cell epitope is altered with amino acid substitutions.
8. (Cancelled)
9. (Cancelled)

10. (Cancelled)
11. (Cancelled)
12. (Cancelled)
13. (Cancelled)
14. (Previously Amended)      A cleaning composition, an animal feed composition, or a composition for treating a textile comprising the variant of claim 2.
15. (Cancelled)
16. (Cancelled)
17. (Cancelled)
18. (Cancelled)
19. (Cancelled)
20. (Cancelled)
21. (Cancelled)
22. (Cancelled)
23. (Cancelled)
24. (Cancelled)
25. (Cancelled)
26. (Cancelled)

27. (Cancelled)
28. (Cancelled)
29. (Previously Added) The variant of claim 2, wherein said polypeptide of interest is a cellulase.
30. (Previously Added) The variant of claim 29, wherein the T-cell epitope of the polypeptide of interest corresponds to the amino acid sequence disclosed in SEQ ID NO: 222 or SEQ ID NO: 223.
31. (Previously Added) The variant of claim 2, wherein said polypeptide of interest is a lipase.
32. (Previously Added) The variant of claim 31, wherein the T-cell epitope of the polypeptide of interest corresponds to the amino acid sequence disclosed in SEQ ID NO: 225 or SEQ ID NO: 226.
33. (Previously Added) The variant of claim 2, wherein said polypeptide of interest is an endoglucosidase H.
34. (Previously Added) The variant of claim 33, wherein the T-cell epitope of the polypeptide of interest corresponds to the amino acid sequence disclosed in SEQ ID NO: 228.
35. (Cancelled)
36. (Cancelled)
37. (Cancelled)
38. (Cancelled)

39. (Previously Added) A cosmetic care formulation for skin, hair or oral care comprising the variant of claim 2.

40. (Cancelled)

41. (Currently Amended) A reduced allergenic variant of a polypeptide of interest, wherein said polypeptide of interest is selected from the group consisting of a cellulase, lipase, endoglucosidase H, carbohydrase, reductase, oxidase, isomerase, transferase, kinase, and phosphatases, ~~and a protease~~ and said polypeptide of interest comprises a T-cell epitope, wherein said variant differs from said polypeptide of interest by having an altered T-cell epitope such that at least two amino acid residues of the T-cell epitope are altered, and wherein an allergenic immunogenic response produced by said variant is less in an individual than the allergenic immunogenic response produced by said polypeptide of interest